ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comprehensive Approach to Secondary HIV Prevention and Care Among Positives (P&T)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01935440
Recruitment Status : Recruiting
First Posted : September 5, 2013
Last Update Posted : March 9, 2017
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Carl Latkin, Johns Hopkins Bloomberg School of Public Health

Brief Summary:
The goal of this study is to conduct an HIV prevention intervention to train HIV seropositive drug users to be peer health educators.

Condition or disease Intervention/treatment Phase
HIV Behavioral: Prevention & Testing Behavioral: Prevention & Testing Control Not Applicable

Detailed Description:
The primary objective of this funded research is to conduct an HIV prevention intervention to train HIV seropositive drug users to be peer health educators to: (1) recruit their high risk social network members for voluntary HIV counseling and testing (VCT) at the research clinic, (2) promote risk reduction among social network members, and (3) promote engagement in HIV care by encouraging HIV seropositive network members to schedule and keep HIV primary care appointments. There will be four types of participants in the Full Trial: 1) Index, 2) Testing Network 3) Longitudinal Network and 4) HIV positive network participants. This longitudinal study includes baseline, 6-months, and 12-month assessments

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Comprehensive Approach to Secondary HIV Prevention and Care Among Positives
Actual Study Start Date : November 1, 2012
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Active Comparator: Prevention & Testing Control
The comparison condition is focused on basic HIV risk reduction , safety and preventing drug overdose.
Behavioral: Prevention & Testing Control
7 group sessions

Experimental: Prevention & Testing Intervention
The intervention condition is training on peer outreach skills which includes talking to HIV positive social network members about HIV care, medication adherence and HIV risk reduction.
Behavioral: Prevention & Testing
6 group sessions, 1 individual session, and 1 dyad session




Primary Outcome Measures :
  1. change in HIV medication adherence [ Time Frame: 6 month ]
  2. change in frequency in attending HIV medical appointments [ Time Frame: 6 month ]

Secondary Outcome Measures :
  1. change in sharing injection equipment [ Time Frame: 6 month ]
  2. change in condom use [ Time Frame: 6 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Index

  1. 18 years old or older
  2. documentation of HIV positive status
  3. report one of following risk behaviors in past 90 days: sharing injection equipment, use of crack cocaine, or unprotected vaginal or anal sex

Testing network

  1. 18 or older
  2. provided testing coupon provided by an index participant

Longitudinal network participant-

  1. tested HIV negative at the Lighthouse via redeeming a testing coupon
  2. reported interacting with index who gave the coupon at least weekly
  3. report one of following risk behaviors in the prior 90 days: sharing injection equipment, use of crack cocaine, or unprotected vaginal or anal sex

Positive Networks

  1. HIV positive
  2. report one of following risk behaviors in the prior 90 days: sharing injection equipment, use of crack cocaine, or unprotected vaginal or anal sex

Exclusion Criteria:

Index- already enrolled in the study as a Network participant

Testing network- already enrolled in the study as a Network participant

Longitudinal network- a) already enrolled in the study as a Network participant b) already enrolled in the study as a Index participant

Positive network- a) already enrolled in the study as a Network participant b) already enrolled in the study as a Index participant


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01935440


Contacts
Contact: Carl Latkin, PhD 410-502-5368 clatkin@jhsph.edu

Locations
United States, Maryland
Lighhouse Studies @ Peer Point Recruiting
Baltimore, Maryland, United States, 21205
Principal Investigator: Carl Latkin, PhD         
Sponsors and Collaborators
Johns Hopkins Bloomberg School of Public Health
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Carl A Latkin, PhD Johns Hopkins Bloomberg School of Public Health

Responsible Party: Carl Latkin, Professor, Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier: NCT01935440     History of Changes
Other Study ID Numbers: R01DA032217 ( U.S. NIH Grant/Contract )
R01DA032217 ( U.S. NIH Grant/Contract )
First Posted: September 5, 2013    Key Record Dates
Last Update Posted: March 9, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Carl Latkin, Johns Hopkins Bloomberg School of Public Health:
HIV, drug use